- Vivacity-MG3 included a 24-week double-blind phase followed by an open-label extension with up to 120 weeks of observation for nipocalimab (IMAAVY) in gMG patients.
- At 96 weeks in the OLE mean MG-ADL fell by 6.47 points and QMG by 5.97 points, with 50% achieving minimal symptom expression (MSE) and 32% sustaining MSE ≥8 weeks.
- Treatment reduced total IgG by >64% and supported corticosteroid tapering, with 57% of patients reaching doses ≤10 or ≤5 mg/day.
- Johnson & Johnson/Janssen plan the EPIC head-to-head open-label study comparing IMAAVY versus efgartigimod, planned to initiate in 2025 and currently enrolling.
Study design and population
Phase 3 Vivacity‑MG3 randomized adults with generalized myasthenia gravis (including anti‑AChR+ and anti‑MuSK+ patients) to nipocalimab (IMAAVY) plus standard of care or placebo for a 24‑week double‑blind phase, followed by an ongoing open‑label extension with up to 120 weeks of observation.
Long‑term efficacy
At 96 weeks in the OLE, mean MG‑ADL decreased by 6.47 points and mean QMG by 5.97 points versus baseline; total IgG fell >64% and 57% of patients tapered corticosteroids to ≤10 or ≤5 mg/day.
Minimal Symptom Expression and quality of life
Post‑hoc analyses from the 24‑week double‑blind phase showed nipocalimab plus SOC made patients four times more likely than placebo to achieve sustained minimal symptom expression (MG‑ADL 0–1 maintained ≥8 weeks), and those with sustained MSE had the largest MG‑QoL‑15r gains.
Safety, mechanism and development plans
Nipocalimab blocks FcRn to reduce circulating IgG, including pathogenic autoantibodies; reported risks include infections, peripheral edema, muscle spasms, hypersensitivity and infusion‑related reactions; Johnson & Johnson plans the EPIC head‑to‑head open‑label study versus efgartigimod, planned to start in 2025 and currently enrolling.
